Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Homotaurine

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 62Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzheon Scientists Discover Endogenous Substance that could affect Alz’s Disease
    Alzheon Scientists Discover Endogenous Substance that could affect Alz’s Disease

    06 Aug 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20180806005263/en/Teva-Announces-Updated-Indication-Vial-Presentation-GRANIX%C2%AE

    BUSINESSWIRE
    06 Aug 2018
    Share Share
    Alzheon says data back plans for phase 3 program
    Alzheon says data back plans for phase 3 program

    23 Jul 2018

    // Phil Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/alzheon-says-data-back-plans-for-phase-3-program

    Phil Taylor FIERCE BIOTECH
    23 Jul 2018
    Share Share
    Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alz
    Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alz

    23 Jul 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20180723005050/en

    BUSINESSWIRE
    23 Jul 2018
    Share Share